SCHEMBL178474

SCHEMBL178474

CNCc1ccn(C)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2259759 0.79 EPHX2 (0.58)
SCHEMBL104749 0.78 EPHX2 (0.49)
SCHEMBL22360305 0.77 EPHX2 (0.45)
SCHEMBL18869739 0.77 KDM4E (0.35)
SCHEMBL24777122 0.76 HTR2C (0.35)
SCHEMBL24186196 0.76 EPHX2 (0.47)
SCHEMBL3305842 0.76 EPHX2 (0.47)
SCHEMBL24613090 0.76 EPHX2 (0.64)
SCHEMBL18924762 0.76 EPHX2 (0.51)
SCHEMBL13853642 0.76 NAMPT (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368122-A1 JAK2 INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS INC (US) 2024-11-07 US disclosed
EP-4387964-A1 JAK2 INHIBITORS AND METHODS OF USE THEREOF Relay Therapeutics, Inc. (US) 2024-06-26 EP disclosed
US-20240092784-A1 CONDENSED HETEROCYCLIC COMPOUND NISSAN CHEMICAL CORPORATION (JP) 2024-03-21 US disclosed
EP-4219500-A1 CONDENSED HETEROCYCLIC COMPOUND Nissan Chemical Corporation (JP) 2023-08-02 EP disclosed
CN-111848572-B Amide compound and preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2023-03-31 CN disclosed
WO-2023027948-A1 JAK2 INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. (US) 2023-03-02 WO disclosed
WO-2023027948-A1 JAK2 INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. (US) 2023-03-02 WO disclosed
WO-2022007677-A1 CD73 INHIBITOR AND APPLICATION IN PHARMACEUTICAL USE 贝达药业股份有限公司 2022-01-13 WO disclosed
EP-3929185-A1 NITROGEN-CONTAINING FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2021-12-29 EP disclosed
CN-111848572-A Amide compound and preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2020-10-30 CN disclosed
US-20110053912-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-03-03 US disclosed
US-20110053912-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-03-03 US disclosed
WO-2010113834-A1 PYRIMIDINE COMPOUND アステラス製薬株式会社 (JP) 2010-10-07 WO disclosed
US-20100093752-A1 PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-04-15 US disclosed
US-7662823-B2 Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-16 US disclosed
US-20090306095-A1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY 2009-12-10 US disclosed
US-20090306095-A1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY 2009-12-10 US disclosed
US-7501420-B2 Composition and antiviral of substituted azaindoleoxoacetic piperazine derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-10 US disclosed
US-20080119480-A1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY 2008-05-22 US disclosed
US-7354924-B2 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2008-04-08 US disclosed